Teva to repay $1.2B for Cephalon’s Conspiring with Generic Firms

Jeffrey Brennan emphasized the significance of a $1.2 billion FTC antitrust settlement on pay-for-delay antitrust drug claims, not only because the amount is “certainly a big number, and a billion is a lot of money,” but also because it is the first FTC case settled since the Supreme Court Actavis ruling on such claims. In future cases, Mr. Brennan added, “The Supreme Court’s rule of reason will apply, and the outcomes will be fact specific and dependent on the weight of the evidence.” Read the full article